Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2025 pubmed

Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients.

Elgarhy. Lamia Hamouda LH; Ramadan. Basma Ramadan Refaey BRR; Sallam. Fersan Abd Allah FAA; Iskandarani. Dalya Ayman DA; Hewedy. El-Sayed Shaaban ES

Key Findings

  • LL‑37 levels were significantly higher in vitiligo lesions and in non‑lesional skin of patients versus healthy controls.
  • Higher LL‑37 expression correlated with disease activity scores (VIDA).
  • The study proposes LL‑37 could be a marker for future lesion development, though this needs more research.

Practical Outcomes

  • For biohackers, the main takeaway is that LL‑37 appears linked to skin autoimmunity, but there are no actionable protocols or dosage recommendations yet. Until further studies show how to safely modulate LL‑37, it remains a biomarker rather than a therapeutic target for longevity or performance goals.

Summary

The study looked at the levels of the antimicrobial peptide LL‑37 in the skin of people with vitiligo, a condition where skin loses pigment. Researchers found higher LL‑37 in both affected and nearby healthy‑looking skin compared to people without vitiligo, and the amount of LL‑37 was linked to how active the disease was. This suggests LL‑37 might play a role in the disease process, but the work does not test any treatments or give clear advice on how to use LL‑37 for health improvement.

Abstract

Vitiligo is a pigmentary disorder acquired and caused by the loss or destruction of melanocytes from the epidermis. There is strong proof that vitiligo is mainly an autoimmune disease. Cathelicidin (LL37), an antimicrobial polypeptide, is an important part of the innate immune system and has a role in different skin autoimmune diseases. The present work aimed to study the immunoexpression of cathelicidin in the vitiligo patients' skin to elucidate its possible role in vitiligo pathogenesis. Twenty vitiligo patients and 20 controls of matched sex and age were included. A 3 mm punch biopsy was taken from the non-lesional and lesional skin of each patient and controlled subjects. Each was stained with hematoxylin and eosin (H&E) and subjected to cathelicidin immunostaining detection. A significant difference was detected between the two studied groups regarding cathelicidin immunohistochemical expression (Pvalue < 0.001). The lesional immunohistochemical expression of cathelicidin showed a mean of 2.85 ± 0.67. The non-lesional immunohistochemical expression of cathelicidin showed a mean of 2.05 ± 0.51 with a statistically significant higher mean value in the patients' group than the controls (P < 0.001) which recommends that cathelicidin may play a role in the vitiligo pathogenesis. The immunohistochemical scores of the lesional and non-lesional cathelicidin levels were significantly related to the VIDA score (p < 0.001 and = 0.016, respectively) which suggests a role of cathelicidin in vitiligo activity. A significant elevation was indicated in the non-lesional cathelicidin expression, indicating that cathelicidin may be able to predict the appearance of future lesions in non-lesional skin, this requires further longitudinal studies to be confirmed.

Study Information

Provider

pubmed

Year

2025

Date

2025-01-28T00:00:00.000Z

DOI

10.1007/s00403-025-03801-2

References

33